Romidepsin for previously treated patients with peripheral or aggressive T-cell lymphomas.
Memorial Sloan-Kettering Cancer Center, New York, New York.
Steven M
SM
Horwitz
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D047630:Depsipeptides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D047630:Depsipeptides; C087123:romidepsin